The global gene therapy market is on a strong upward trajectory, underpinned by rapid scientific advancements and the rising burden of rare genetic diseases. According to Fortune Business Insights, the market was valued at USD 4.29 billion in 2025 and is projected to grow from USD 5.2 billion in 2026 to USD 11.33 billion by 2034, registering a CAGR of 10.20% during the forecast period.
Gene therapy is a medical technique that uses genes to treat, prevent, or cure diseases. It works by introducing new copies of a gene or correcting defective genes within a patient's cells. These therapies have demonstrated high efficacy against both congenital disorders such as sickle cell anemia and acquired conditions such as leukemia, making them one of the most transformative innovations in modern medicine.
The primary driver of market growth is the increasing global prevalence of genetic disorders, including spinal muscular atrophy (SMA), hemophilia, β-thalassemia, and inherited retinal diseases. The World Federation of Hemophilia reported 218,804 patients with hemophilia globally in 2023, reflecting the scale of unmet medical need. This rising disease burden is pushing demand for curative, root-cause-targeting therapies.
Advancements in gene delivery systems also offer significant growth opportunities. In May 2025, Dyno Therapeutics launched three new adeno-associated virus (AAV) capsid gene delivery vectors targeting the eye, musculoskeletal system, and central nervous system — improving tissue specificity and therapeutic efficiency. Additionally, in June 2025, SpliceBio secured Series B funding of USD 127.7 million to advance its gene therapy pipeline.
Despite strong growth prospects, the market faces considerable hurdles. The prohibitively high cost of gene therapies remains a critical barrier. For instance, CSL's hemophilia B gene therapy, approved by the U.S. FDA in December 2022, carries a one-time treatment price of USD 3.5 million. Such costs create financial obstacles for patients and healthcare systems alike. Additionally, maintaining long-term clinical efficacy is a significant challenge, as transgene expression can decline over time due to immune responses or promoter silencing.
By Product: Zolgensma dominated the product segment in 2025, valued at USD 1.24 billion, owing to its proven durability and application in treating life-threatening SMA in infants. Roctavian is expected to register the highest CAGR of 38.72% through 2034.
By Vector Type: Viral vectors held a dominant market share of 98.46% in 2026, favored for their high transduction efficiency and ability to achieve long-lasting gene expression.
By Indication: Genetic disorders led with a 31.4% share in 2025, driven by the growing focus on personalized therapeutic approaches.
By End User: Hospitals & clinics dominated with a 55.96% market share in 2026, functioning as central hubs for clinical trials and rigorous therapy monitoring.
North America held 24.60% of the global market share in 2025, valued at USD 1.05 billion, supported by robust FDA approvals, strong biotech presence, and venture capital funding. Europe was the largest regional contributor, accounting for 54.00% of total market revenue in 2025 at USD 2.32 billion, driven by supportive regulatory pathways and national reimbursement programs. Asia Pacific contributed approximately 9.20% (USD 0.40 billion) in 2025 and is expected to grow steadily, with China and India emerging as key growth markets.
Prominent companies shaping the global gene therapy landscape include:
Q1. What is the size and share of the global gene therapy market? The global gene therapy market was valued at USD 4.29 billion in 2025 and is projected to grow from USD 5.2 billion in 2026 to USD 11.33 billion by 2034, at a CAGR of 10.20%. North America accounted for 24.60% of the global market share in 2025, while Europe led all regions with a dominant 54.00% revenue share.
Q2. What are the major factors driving gene therapy market growth? Key growth drivers include the rising global prevalence of genetic disorders such as SMA and hemophilia, advancements in viral vector and gene delivery technologies, increasing R&D investments, and a growing pipeline of regulatory-approved therapies.
Q3. Which product segment leads the gene therapy market? Zolgensma held the leading product segment share in 2025, valued at USD 1.24 billion. Its dominance is attributed to its proven long-term durability — with data supporting efficacy up to 7.5 years post-dosing — and its use in treating spinal muscular atrophy, a common and life-threatening condition in infants.
Source: Fortune Business Insights – Gene Therapy Market Report https://www.fortunebusinessinsights.com/industry-reports/gene-therapy-market-100243